NCT02337543View on ClinicalTrials.gov

NEO6860, a TRPV1 Antagonist, First in Human Study

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Osteoarthritis, Knee
Interventions
DRUG

NEO6860

NEO6860 is an NCE acting as a TRPV1 antagonist

DRUG

Placebo

Placebo

Trial Locations (1)

LS2 9LH

Covance Cru, Leeds

Sponsors

Lead Sponsor

Neomed Institute

Collaborators (1)

Covance
All Listed Sponsors
collaborator

Covance

INDUSTRY

lead

Neomed Institute

OTHER